Ferozsons Laboratories announced Financial Results for the period ended June 30, 2017.
The company’s Net Revenue for the period decreased by 57.67 percent in the outgoing year, whereas the Profit after Taxation for the Period decreased by 81 percent.
The board did not recommend any interim Cash Dividend, no bonus or right shares.
Comparison of Key Financials
| Unconsolidated Profit and Loss Account – For the Twelve Months Ended | |||
| Key Financials | 2017 | 2016 | % Change |
| Amounts in PKR | |||
| Net Revenue | 4,311,441,718 | 10,186,496,154 | -57.67% |
| Cost of Sales | 2,534,669,504 | 6,077,657,868 | -58.30% |
| Gross Profit | 1,776,772,214 | 4,108,838,286 | -56.76% |
| Admin: Expenses | 289,129,914 | 276,235,535 | 4.67% |
| Selling & Dist: Expenses | 913,763,385 | 1,033,035,251 | -11.55% |
| Other Expenses | 3,216,963 | 260,905,050 | -98.77% |
| Other income | 47,849,556 | 126,515,313 | -62.18% |
| Profit from Operations | 618,511,508 | 2,665,177,763 | -76.79% |
| Finance Costs | 16,293,573 | 11,152,570 | 46.10% |
| Profit before Taxation | 602,217,935 | 2,654,025,193 | -77.31% |
| Taxation | 208,553,225 | 549,538,096 | -62.05% |
| Profit after Taxation | 393,664,710 | 2,104,487,097 | -81.29% |
| EPS – Basic & diluted | 13.04 | 69.72 | -81.30% |
Company release on Earnings Report can be accessed here.
Posted on: 2017-08-30T14:50:00+05:00
